Agenus (AGEN): What's Ahead For The Stock In Q4 Earnings?
Zacks Investment Research | Feb 27, 2017 06:14AM ET
Agenus Inc. (NASDAQ:AGEN) is expected to report fourth-quarter 2016 results during this month. Last quarter, Agenus delivered a negative earnings surprise of 46.88%. Let’s see how things are shaping up for the company this quarter.
Agenus’ share price has decreased 6.5% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 6.1%.
Factors at Play
Agenus is an immuno-oncology company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.The company earns revenues only through fees received under collaboration and license agreements
Currently, the company is evaluating AGEN1884 in a phase I study and INCAGN01876 in a phase I/II study for the treatment of solid tumors.
The company has initiated phase I study for OX40 aganist INCAGN1949 in collaboration with Incyte. Agenus has also started phase I study for PD-1 antagonist AGEN2034 and AutoSynVax. Going ahead, the company plans to initiate studies on its second anti-CTLA-4 antibody, AGEN2041, in 2017. Agenus also expects to begin combination studies on AGEN2034 and AGEN1884 in the second half of 2017.
In its fourth-quarter conference call, investor should remain focus on the company’s update on the initiation of combination studies on these antibodies as well as the advancement of additional checkpoint modulator antibodies and vaccines into the clinic in the coming quarters.
We remind investors that Agenus’ lead candidate and several backup antibodies were selected by Merck & Co., Inc. (NYSE:MRK) for an undisclosed checkpoint target. Under the terms of the agreement, Agenus is eligible to receive up to $100 million in milestone payments, in addition to royalties on worldwide product sales.
In January this year, Agenus entered into a clinical trial collaboration with the National Cancer Institute (NCI) to evaluate Prophage (HSPPC-96), in conjunction with Merck’s PD-1 therapy, Keytruda. A phase II study will evaluate the effect of Prophage, in conjunction with Keytruda, on the overall survival rate of patients with newly diagnosed glioblastoma (ndGBM).
Surprise History
Agenus’ track record has been disappointing so far. The company has surpassed estimates in only once in the trailing four quarters and missed the same in all the other occasions, bringing the average negative surprise to 9.02%.
Get The News You Want
Earnings Whispers
Our proven model does not conclusively show that Agenus is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP Filter .
Zacks Rank: Agenus currently carries a Zacks Rank #3, which when combined with a 0.00% ESP, makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrants a Look
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter. You can see .
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has an Earnings ESP of +20% and a Zacks Rank #2. The company is scheduled to release results on Mar 1.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release results on Mar 2.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.